159 related articles for article (PubMed ID: 34366859)
1. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration.
Parra-Guillen ZP; Freshwater T; Cao Y; Mayawala K; Zalba S; Garrido MJ; de Alwis D; Troconiz IF
Front Pharmacol; 2021; 12():705443. PubMed ID: 34366859
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer.
Tran TQ; Grein J; Selman M; Annamalai L; Yearley JH; Blumenschein WM; Sadekova S; Chackerian AA; Phan U; Wong JC
Mol Ther Oncol; 2024 Jun; 32(2):200807. PubMed ID: 38745749
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling.
Parra-Guillen ZP; Sancho-Araiz A; Mayawala K; Zalba S; Garrido MJ; de Alwis D; Troconiz IF; Freshwater T
Clin Pharmacol Ther; 2023 Sep; 114(3):623-632. PubMed ID: 37170933
[TBL] [Abstract][Full Text] [Related]
4. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
Rudin CM; Pandha HS; Zibelman M; Akerley WL; Harrington KJ; Day D; Hill AG; O'Day SJ; Clay TD; Wright GM; Jennens RR; Gerber DE; Rosenberg JE; Ralph C; Campbell DC; Curti BD; Merchan JR; Ren Y; Schmidt EV; Guttman L; Gupta S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36669791
[TBL] [Abstract][Full Text] [Related]
5. Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
Andtbacka RHI; Curti B; Daniels GA; Hallmeyer S; Whitman ED; Lutzky J; Spitler LE; Zhou K; Bommareddy PK; Grose M; Wang M; Wu C; Kaufman HL
J Clin Oncol; 2021 Dec; 39(34):3829-3838. PubMed ID: 34464163
[TBL] [Abstract][Full Text] [Related]
6. A physiologically based pharmacokinetic model for V937 oncolytic virus in mice.
Peribañez-Dominguez S; Parra-Guillen ZP; Freshwater T; Troconiz IF
Front Pharmacol; 2023; 14():1211452. PubMed ID: 37771727
[No Abstract] [Full Text] [Related]
7. SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus.
Deng JZ; Rustandi RR; Swartz A; Shieh Y; Baker JB; Vlasak J; Wang S; Loughney JW
Mol Ther Oncolytics; 2022 Mar; 24():139-147. PubMed ID: 35024440
[TBL] [Abstract][Full Text] [Related]
8. Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification.
Deng JZ; Rustandi RR; Barbacci D; Swartz AR; Gulasarian A; Loughney JW
Hum Gene Ther; 2022 Jul; 33(13-14):765-775. PubMed ID: 35387488
[TBL] [Abstract][Full Text] [Related]
9. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.
Silk AW; O'Day SJ; Kaufman HL; Bryan J; Norrell JT; Imbergamo C; Portal D; Zambrano-Acosta E; Palmeri M; Fein S; Wu C; Guerreiro L; Medina D; Bommareddy PK; Zloza A; Fox BA; Ballesteros-Merino C; Ren Y; Shafren D; Grose M; Vieth JA; Mehnert JM
Cancer Immunol Immunother; 2023 Jun; 72(6):1405-1415. PubMed ID: 36445410
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
Relph K; Annels N; Smith C; Kostalas M; Pandha H
Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
[TBL] [Abstract][Full Text] [Related]
12. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
13. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21.
Au GG; Lindberg AM; Barry RD; Shafren DR
Int J Oncol; 2005 Jun; 26(6):1471-6. PubMed ID: 15870858
[TBL] [Abstract][Full Text] [Related]
14. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
15. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.
Shafren DR; Au GG; Nguyen T; Newcombe NG; Haley ES; Beagley L; Johansson ES; Hersey P; Barry RD
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):53-60. PubMed ID: 14734451
[TBL] [Abstract][Full Text] [Related]
18. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
19. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic viruses: do they have a role in anti-cancer therapy?
Prestwich RJ; Errington F; Harrington KJ; Pandha HS; Selby P; Melcher A
Clin Med Oncol; 2008; 2():83-96. PubMed ID: 21892269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
